According to Zhitong Finance App, Shanghai Laishi (002252.SZ) announced that Nanyue Biopharmaceutical Co., Ltd. (“Nanyue Biopharmaceutical”), a wholly-owned subsidiary of the company, recently received a “Drug Registration Certificate” for human fibrinogen issued by the State Drug Administration. Human fibrinogen is produced from healthy human plasma through separation, purification, and virus removal, inactivation treatment, and freeze-drying. This product from Nanyue Biotech is used for congenital fibrinogen reduction or deficiency.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.